View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
November 1, 2011

Pfizer acquires Icagen

Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.

Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.

As per the agreement, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6 in cash, without interest and less any applicable withholding and transfer taxes.

Icagen is now part of Pfizer’s worldwide R&D organisation, and will be integrated into Neusentis, Pfizer’s research unit.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena